Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 220

Sort by

Sort Order Select

Journal Articles

Characterization of BCR-ABL Specific CD4+ T Cells and Their Role in Controlling Ph+ Acute Lymphoblastic Leukemia

Sean I. Tracy, MD PhD, Can Hekim, MSc,PhD, Michael Farrar, PhD

Blood (2019) 134 (Supplement_1): 1345.

https://doi.org/10.1182/blood-2019-124205

Published: 2019

Journal Articles

BCR-ABL and Src Family Kinases Induce YAP Tyrosine Phosphorylation Resulting in Survivin and Cyclin D1 Expression in Chronic Myeloid Leukemia Cells

Toshiyuki Hori, MD PhD, Kenta Moriyama, MS

Blood (2019) 134 (Supplement_1): 5366.

https://doi.org/10.1182/blood-2019-124643

Published: 2019

Journal Articles

The ''Gatekeeper'' Mutation T315I in BCR/ABL Confers Additional Oncogenic Activities to Philadelphia Chromosome Positive Leukemia

Usva Zafar, BSc, Mohammed Yusuf, PhD, Rikhia Chakraborty, PhD, El-Nasir M A Lalani, BSc MBChB FRCPath PhDFHEA, Afsar Ali Mian, BSc, MPhil, PhD

Blood (2019) 134 (Supplement_1): 5196.

https://doi.org/10.1182/blood-2019-131694

Published: 2019

Journal Articles

Studying Methylation Status of Protein Tyrosine Phosphatase Receptor Gamma (PTPRG) in Chronic Myeloid Leukemia Patients in the State of Qatar

Mohamed Ismail, BS, MSc, Marzia Vezzalini, Ali Al Sayab, Maria Monne, Vinod Gupta, Govundarajulu Varadharaj, Mohamed Alsharshani, Mohamed Yassin, Claudio Sorio, MD PhD, Helmout Modjtahedi, Nader I. Al-Dewik, PhD

Blood (2018) 132 (Supplement 1): 5124.

https://doi.org/10.1182/blood-2018-99-113482

Published: 2018

Journal Articles

Lncrna RP1-68D18.2 Promotes K562 Cell Line Resistance to Imatinib through CD44 and Its Downstream Signal Molecules

Tianyou Yan, Yuping Gong, MD

Blood (2018) 132 (Supplement 1): 5149.

https://doi.org/10.1182/blood-2018-99-115865

Published: 2018

Journal Articles

Therapeutic Targeting of HSP90 in AML and ALL

Sanil Bhatia, PhD, Heinz Ahlert, Msc, Benedikt Frieg, PhD, Arndt Borkhardt, MD, Holger Gohlke, PhD, Thomas Kurz, Julia Hauer, MD

Blood (2018) 132 (Supplement 1): 4680.

https://doi.org/10.1182/blood-2018-99-120362

Published: 2018

Journal Articles

Heterogeneous BCR-ABL Signal Patterns Identified By Fluorescence in Situ Hybridization Can Predict Leukemic Clonal Evolution and Poor Prognosis in BCR-ABL-Positive Leukemia

Zhang Zhanglin, Wan Lagen, Jiang Mei, Liu Shuyuan, Guo Yang, Li Fei, PhD MD

Blood (2017) 130 (Supplement 1): 1441.

https://doi.org/10.1182/blood.V130.Suppl_1.1441.1441

Published: 2017

Journal Articles

Parthenolide and DMAPT Induce Cell Death in Chronic Myeloid Leukemia Cells Via Generation of Reactive Oxygen Species

Gabriela Flores-López, PhD Candidate, Hector Mayani, PhD, María Antonieta Chávez-Gonzalez, PhD

Blood (2016) 128 (22): 4242.

https://doi.org/10.1182/blood.V128.22.4242.4242

Published: 2016

Journal Articles

ETS1 Expression Is Upregulated in Chronic Myeloid Leukemia (CML) and the ETS1 Transcriptional Program Correlates with Disease Progression Towards Blast Crisis

Christophe Desterke, PhD, Maud Voldoire, MD, Nathalie Sorel, Marie Laure Bonnet, Sarah Pagliaro, PharmD, Annelise Bennaceur-Griscelli, MD PhD, Emilie Cayssials, MD, Jean-Claude Chomel, PharmD PhD, Ali G Turhan, MD, PhD

Blood (2016) 128 (22): 442.

https://doi.org/10.1182/blood.V128.22.442.442

Published: 2016

Journal Articles

Targeting Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia with a Novel Transcriptional Inhibitor

Shintaro Maeda, Ken Morita, MD, PhD, Kensho Suzuki, Hiroshi Sugiyama, PhD, Souichi Adachi, MD, PhD, Yasuhiko Kamikubo, MD, PhD

Blood (2016) 128 (22): 2737.

https://doi.org/10.1182/blood.V128.22.2737.2737

Published: 2016

Journal Articles

The Long Non-Coding RNA NEAT1 Modulates Imatinib-Induced Apoptosis in CML Cells

Chengwu Zeng, Sichu Liu, Lijian Yang, Shaohua Chen, Yangqiu Li

Blood (2015) 126 (23): 4019.

https://doi.org/10.1182/blood.V126.23.4019.4019

Published: 2015

Journal Articles

Bone Marrow Lymphocytic Status during Tyrosine Kinase Inhibitor Therapy and Its Relation to Therapy Response in Chronic Phase Chronic Myeloid Leukemia Patients

Mohamed El Missiry, MD MSc, Shady Adnan, MD MSc, Hanna Rajala, MD PhD, Ahmed Al-Samadi, DDS, PhD, Marja Ekblom, Berit Markevän, MD PhD, Ingbritt Åstrand-Grundström, Maren Wold, Birgitte Ravn Juhl, MD dr.MDsci, Ole Weis Bjerrum, MD DMSc, Inger Haulin, Kimmo Porkka, MD PhD, Ulla Olsson-Strömberg, Henrik Hjorth-Hansen, MD PhD, Satu Mustjoki, MD PhD

Blood (2015) 126 (23): 4027.

https://doi.org/10.1182/blood.V126.23.4027.4027

Published: 2015

Journal Articles

A Novel TNF-Alpha Antibody Based Therapeutic Approach to Target Leukemic Stem Cells in Bcr-Abl Disease

Oliver Herrmann, Msc, Claudia Schubert, Msc, Tom Luedde, MD PhD, Till Braunschweig, MD, Steffen Koschmieder, MD, Tim H Brümmendorf, MD, Mirle Schemionek, PhD

Blood (2015) 126 (23): 15.

https://doi.org/10.1182/blood.V126.23.15.15

Published: 2015

Journal Articles

Patients with Chronic Myeloid Leukemia Show Different Modulation of MYB-Dependent Oncogenic Pathway in the Course of Hematopoietic Differentiation upon Sensitivity to the TKI Treatment

Klara Srutova, Nikola Curik, Koblihova Jitka, Filipp Savvulidi, Hana Klamova, Danilo Perrotti, Tomas Stopka, Katerina Machova Polakova

Blood (2015) 126 (23): 1243.

https://doi.org/10.1182/blood.V126.23.1243.1243

Published: 2015

Journal Articles

Tyrosine Kinase Inhibitor Imatinib Enhances Tumor Immunity By Depleting Functionally Mature Regulatory T Cells

Shinsuke Noguchi, MD, Hiroyoshi Nishikawa, MD, PhD, Hirobumi Saitoh, MD, PhD, Atsushi Ohshima, MD, PhD, Kenichi Sawada, MD, PhD, Shimon Sakaguchi, MD PhD, Naoto Takahashi, MD PhD FJSIM

Blood (2015) 126 (23): 2219.

https://doi.org/10.1182/blood.V126.23.2219.2219

Published: 2015

Journal Articles

Generation of BCR-ABL Reactive CD4+ T Helper Cells By Reprograming and Redifferentiation

Norihiro Ueda, MD, Yasusi Uemura, PhD, Rhong Zhang, MD PhD, Shuichi Kitayama, Yutaka Yasui, Minako Tatsumi, Tian-Yi Liu, MD PhD, Kiyotaka Kuzushima, MD PhD, Hitoshi Kiyoi, MD PhD, Tomoki Naoe, MD PhD, Shin Kaneko, MD PhD

Blood (2015) 126 (23): 3424.

https://doi.org/10.1182/blood.V126.23.3424.3424

Published: 2015

Journal Articles

Disruption of the Peripheral Lymphoid Niche Contributes to Lymphopenia in CML Patients Undergoing Imatinib Treatments

Stephanie Thiant, PhD, Moutuaata M.Moutuou, Philippe Laflamme, Radia Sidi Boumedine, Fanny Larochelle, Dominique Leboeuf, Denis-Claude Roy, MD, Martin Guimond, PhD

Blood (2015) 126 (23): 5165.

https://doi.org/10.1182/blood.V126.23.5165.5165

Published: 2015

Journal Articles

Differential Signaling through p190 and p210 Forms of BCR-ABL Fusion Proteins Revealed By Proteomic Analysis

Jevon Cutler, Rahia Tahir, Jingnan Han, Raja Sekhar Nirujogi, Tai-Chung Huang, MD, Xianrong Wong, Saradhi Mallampati, Xiaoping Sun, MD PhD, Patrick Brown, MD, Karen Reddy, PhD, Akhilesh Pandey, MD PhD

Blood (2015) 126 (23): 3651.

https://doi.org/10.1182/blood.V126.23.3651.3651

Published: 2015

Journal Articles

The Allosteric Inhibitor ABL001 Is Susceptible to Resistance in Vitro Mediated By Overexpression of the Drug Efflux Transporters ABCB1 and ABCG2

Laura N Eadie, PhD, Verity A Saunders, BSc (Hons), Tamara M Leclercq, PhD, Susan Branford, PhDFFSc (RCPA), Deborah L White, PhD FFSc (RCPA), Timothy P. Hughes, MD MBBS, FRACP, FRCPA

Blood (2015) 126 (23): 4841.

https://doi.org/10.1182/blood.V126.23.4841.4841

Published: 2015

Journal Articles

Model-Based Characterization of the Molecular Response Dynamics of Tyrosine Kinase Inhibitor (TKI)-Treated CML Patients – a Comparison of Imatinib and Dasatinib First-Line Therapy

Ingmar Glauche, Christoph Baldow, Sabine Fröhlich, Philipp Schulze, Amit Roy, Milayna Subar, Xiaoning Wang, Ingo Roeder, MD

Blood (2014) 124 (21): 4562.

https://doi.org/10.1182/blood.V124.21.4562.4562

Published: 2014

NARROW

Characterization of BCR-ABL Specific CD4+ T Cells and Their Role in Controlling Ph+ Acute Lymphoblastic Leukemia

BCR-ABL and Src Family Kinases Induce YAP Tyrosine Phosphorylation Resulting in Survivin and Cyclin D1 Expression in Chronic Myeloid Leukemia Cells

The ''Gatekeeper'' Mutation T315I in BCR/ABL Confers Additional Oncogenic Activities to Philadelphia Chromosome Positive Leukemia

Studying Methylation Status of Protein Tyrosine Phosphatase Receptor Gamma (PTPRG) in Chronic Myeloid Leukemia Patients in the State of Qatar

Lncrna RP1-68D18.2 Promotes K562 Cell Line Resistance to Imatinib through CD44 and Its Downstream Signal Molecules

Therapeutic Targeting of HSP90 in AML and ALL

Heterogeneous BCR-ABL Signal Patterns Identified By Fluorescence in Situ Hybridization Can Predict Leukemic Clonal Evolution and Poor Prognosis in BCR-ABL-Positive Leukemia

Parthenolide and DMAPT Induce Cell Death in Chronic Myeloid Leukemia Cells Via Generation of Reactive Oxygen Species

ETS1 Expression Is Upregulated in Chronic Myeloid Leukemia (CML) and the ETS1 Transcriptional Program Correlates with Disease Progression Towards Blast Crisis

Targeting Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia with a Novel Transcriptional Inhibitor

The Long Non-Coding RNA NEAT1 Modulates Imatinib-Induced Apoptosis in CML Cells

Bone Marrow Lymphocytic Status during Tyrosine Kinase Inhibitor Therapy and Its Relation to Therapy Response in Chronic Phase Chronic Myeloid Leukemia Patients

A Novel TNF-Alpha Antibody Based Therapeutic Approach to Target Leukemic Stem Cells in Bcr-Abl Disease

Patients with Chronic Myeloid Leukemia Show Different Modulation of MYB-Dependent Oncogenic Pathway in the Course of Hematopoietic Differentiation upon Sensitivity to the TKI Treatment

Tyrosine Kinase Inhibitor Imatinib Enhances Tumor Immunity By Depleting Functionally Mature Regulatory T Cells

Generation of BCR-ABL Reactive CD4+ T Helper Cells By Reprograming and Redifferentiation

Disruption of the Peripheral Lymphoid Niche Contributes to Lymphopenia in CML Patients Undergoing Imatinib Treatments

Differential Signaling through p190 and p210 Forms of BCR-ABL Fusion Proteins Revealed By Proteomic Analysis

The Allosteric Inhibitor ABL001 Is Susceptible to Resistance in Vitro Mediated By Overexpression of the Drug Efflux Transporters ABCB1 and ABCG2

Model-Based Characterization of the Molecular Response Dynamics of Tyrosine Kinase Inhibitor (TKI)-Treated CML Patients – a Comparison of Imatinib and Dasatinib First-Line Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only